Drug intelligence / Profile preview

autologous stem cell therapy (Andalusian Initiative for Advanced Therapies)

Development stage: Unknown
Lead developer: Red Andaluza de Terapias Avanzadas
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intra-arterial

Overview

This autologous stem cell therapy is an advanced medicinal product developed by the Andalusian Initiative for Advanced Therapies (IATA) and the Fundación Pública Andaluza Progreso y Salud. It involves the intra-arterial administration of patient-derived cells, specifically comparing the efficacy of bone marrow mononuclear cells (BM-MNCs), CD133+ endothelial progenitor cells (EPCs), and adipose-derived mesenchymal stem cells (AD-MSCs). The therapy is primarily indicated for patients with type 2 diabetes mellitus suffering from critical limb ischemia (CLI). Its mechanism of action centers on stimulating neovascularization and therapeutic angiogenesis to restore blood flow to ischemic tissues, thereby reducing the risk of major amputation. Additionally, the therapy aims to modulate inflammatory cytokines and improve insulin sensitivity, potentially reducing the patient's exogenous insulin requirements.

Other names: stem cell-Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud-critical limb ischemia-type 2 diabetes mellitusStem cell infusionBM-MNCsCD133+ EPCsAD-MSCs

Beyond the preview

Go deeper on autologous stem cell therapy (Andalusian Initiative for Advanced Therapies).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous stem cell therapy (Andalusian Initiative for Advanced Therapies).

Explore the full profile